If you are watching Pfizer right now and feeling uncertain about whether to stay, buy, or even take profits, you are definitely not alone. Over the last month, Pfizer’s stock has climbed 5.6%, including a recent 3.1% push in just a week. But this rebound is set against a much tougher long-term backdrop, with shares still down 1.3% year-to-date and off 3.7% over the past year. The bigger picture shows a longer slide of 26.1% in three years and nearly 5% in five years. Clearly, investors have had to reckon with swingy sentiment, tough industry news, and evolving risks.

Part of the recent buzz comes from headlines about Pfizer’s role in ongoing drug price negotiations with the Trump administration, pushing for deals that could reshape the pricing landscape for years to come. These talks hint at changing profit dynamics and risk perception among investors, as government pressure and new policies weigh on the sector. Yet, share price does not always move in lock step with the true value of the business. That is where getting under the hood can pay off.

That is why we rely on a structured, numbers-first approach to valuation. By checking Pfizer’s fundamentals across key valuation methods, we see the company is undervalued in five out of six categories, earning a value score of 5. This positions it as a potential bargain if you trust the metrics. Next, let’s walk through those individual valuation checks and discuss how each approach sees Pfizer’s upside and downside. And if you think valuation is just about ratios and spreadsheets, hang on until the end. I’ll show you what really matters most when sizing up a stock like this.

Why Pfizer is lagging behind its peers

The Discounted Cash Flow (DCF) model estimates what a company is really worth by forecasting its future cash flows and then discounting those numbers back to today. For Pfizer, this means projecting its future Free Cash Flow and figuring out what those future dollars are worth in the present, using a model known as the 2 Stage Free Cash Flow to Equity approach.

Currently, Pfizer generates Free Cash Flow of $12.0 billion. Analyst estimates predict steady growth, with annual FCF expected to reach about $18.2 billion by 2026 and gradually rise to $18.1 billion by 2028. The model, using both analyst forecasts and longer-term extrapolations, projects the company's FCF at $18.1 billion in five years and $18.1 billion to $18.7 billion in the years after, through 2035.

Based on these future cash flows, the intrinsic value per share is calculated at $67.98. When compared to where the shares trade today, the DCF model shows a 61.4% discount to fair value, suggesting that the stock may be significantly undervalued.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Pfizer.

Our Discounted Cash Flow (DCF) analysis suggests Pfizer is undervalued by 61.4%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

The Price-to-Earnings (P/E) ratio is one of the most widely used valuation tools, especially for profitable companies like Pfizer. This metric helps investors compare how much they are paying for every dollar of a company's earnings, and it is particularly relevant when a business has a predictable profit stream.

What counts as a “normal” or “fair” P/E ratio depends on a company’s growth prospects and risks. In general, faster-growing, lower-risk companies tend to trade at higher P/E multiples, while slower or more uncertain businesses trade at lower ones. For context, Pfizer’s current P/E stands at 13.9x, which trails both the Pharmaceuticals industry average of 18.3x and its peer average of 18.9x.

But benchmarks alone do not tell the whole story. That is where the Simply Wall St Fair Ratio comes in, a custom valuation multiple that reflects Pfizer’s unique profile: its earnings growth outlook, industry, margins, size, and risk factors. For Pfizer, the Fair Ratio is estimated at 22.4x, suggesting that, based on its fundamentals and expected performance, the market might reasonably value Pfizer at a higher P/E than its current level.

Because the Fair Ratio incorporates more granular details than simple peer or industry comparisons, it provides a more targeted view of what Pfizer is truly worth in today’s market. With the current P/E at 13.9x well below the Fair Ratio of 22.4x, this suggests the stock is undervalued on this metric.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation, so let's introduce you to Narratives. Narratives are a powerful tool that allow you to tell the story behind the numbers, combining your view of Pfizer's future, such as how its revenue or margins might change, with your assumptions about what the company should be worth.

A Narrative links your perspective on Pfizer as a business to financial forecasts and ultimately to a personal fair value estimate, turning abstract financials into an actionable investment idea. On Simply Wall St's Community page, millions of investors easily create and update Narratives to reflect their own outlook or to react to new events, such as company news or earnings releases.

By comparing your Narrative's fair value to the actual share price, you can decide whether to buy, sell, or hold with genuine conviction. Narratives update automatically as fresh information emerges, ensuring your investment thesis stays relevant without extra effort.

For example, some investors see ongoing oncology growth and new drug launches justifying fair values above $35, while others focus on regulatory and pricing risks, leading to targets as low as $24. This range reflects how your story drives your estimate. Narratives let you invest based on your view and see how it compares to the crowd, making your decision smarter and more personalized.

For Pfizer, we'll make it really easy for you with previews of two leading Pfizer Narratives:

???? Pfizer Bull Case

Fair Value: $28.86

Undervalued by 9.0%

Revenue Growth Rate: -2.25%

Long-term growth potential driven by expansion of innovative oncology and biologics pipelines, strategic business development, and ongoing digitalization.

Emerging markets and operational improvements are seen as key drivers of future revenue opportunities and margin expansion despite near-term revenue declines.

Main risks include regulatory and political pressures on drug pricing, looming patent expirations, and intensified competition that could threaten revenue streams.

???? Pfizer Bear Case

Fair Value: $24.00

Overvalued by 9.5%

Revenue Growth Rate: -4.21%

Tightening drug price regulations, patent expirations, and increased competition are expected to weigh heavily on Pfizer’s revenue and margins in the future.

Ongoing dependence on new R&D and pipeline launches may not fully offset the declining revenues from legacy products facing generic threats.

Regulatory reforms and market changes indicate that top-line sales and earnings could remain under persistent downward pressure through the decade.

Do you think there's more to the story for Pfizer? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include PFE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com